CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 140,187 enrolled
Drug / intervention
Dabigatran etexilate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03006341
NCT03006341N/ACompleted
CompareCT.gov

Validation of Predictors for Oral Anticoagulant Medication Choice Using EMR Data

Boehringer Ingelheim·observational·Posted Dec 30, 2016·Updated Mar 22, 2019

In Brief

An observational study evaluating Dabigatran etexilate and Warfarin for Atrial Fibrillation. Completed, enrolled 140,187 participants across 1 site.

Detailed Summary

The objectives of this study are, first, to identify select clinical covariates from electronic medical records (EMR) that might be associated with initiation of oral anticoagulant medications (dabigatran or warfarin) in patients with non-valvular atrial fibrillation (NVAF) at risk for stroke; second, to quantify the association between EMR-based clinical characteristics and patterns of insurance claims; third, to assess the potential for unmeasured confounding in dabigatran vs warfarin comparative effectiveness and safety studies based on administrative claims databases.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedDec 30, 2016
Enrollment StartFeb 28, 2017
Primary CompletionMay 9, 2017
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.5 years ago

Interventions

Dabigatran etexilatedrug

observed upto 12 months

Warfarindrug

Observed upto 12 months